IP Library Granted Patent US 12,472,377
Granted Patent B2
US 12,472,377 · App. 18/928,126 · Granted Nov 18, 2025

Filtering eyewear and optics for ocular photo-bio-stimulation

Inventors: Ronald Blum (Atlanta, GA); Jack Loeb (Fisher Island, FL); Anita Broach (Christiansburg, VA)
Assignee: NeuroRays, LLC
A61N5/0622A61N2005/0648A61N2005/0663A61N2005/0667
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,472,377
App. No.
18/928,126
Granted
Nov 18, 2025
Kind
B2
Abstract

A device providing ocular photo-bio-stimulation therapy.

Claims (29)

1 . A lens or optical system, including a lens or optic comprising a central optical power zone having optical power or plano optical power, and the lens or optic further comprising one or more peripheral optical power zones peripheral to the central optical power zone having more minus optical power compared to the optical power or plano optical power of the central optical power zone wherein the central optical power zone includes transmits a first set of longitudinal chromatic aberration wavelength bands of blue, green, and red, wherein the one or more peripheral optical power zones transmit a second set of longitudinal chromatic aberration wavelength bands of blue, green, and red, wherein the first and second sets of longitudinal chromatic aberration wavelength bands are provided as concentric circles wherein the central optical power zone of the lens or optic further comprises one or more refractive surfaces, wherein the one or more peripheral optical power zones further comprise one or more refractive, diffractive, or diffusive surfaces, wherein the first set of longitudinal chromatic aberration wavelength bands includes a first blue longitudinal chromatic aberration wavelength band, wherein the second set of longitudinal chromatic aberration wavelength bands includes a second blue longitudinal chromatic aberration wavelength band, and wherein the second blue longitudinal chromatic aberration wavelength band is focused closer to a retina of a wearer's eye than the first blue longitudinal chromatic aberration wavelength band.

2 . The system of claim 1 , wherein the second blue longitudinal chromatic aberration wavelength band focuses one or more blue light wavelengths in or on the retina of the wearer's eye.

3 . The system of claim 1 , wherein the optical power of the one or more peripheral optical power zones is within a range of 0.50D to 5.00D more minus or less plus optical power than the optical power of the central optical power zone.

4 . The system of claim 1 , wherein the central optical power zone has a blended abbe number determined from a lens material and any coatings on the lens material of the central optical power zone, and wherein the central optical power zone's blended abbe number is greater than a blended abbe number of the one or more peripheral optical power zones.

5 . The system of claim 1 , wherein the central optical power zone is physically thinner than the one or more peripheral optical power zones.

6 . The system of claim 1 , wherein light transmitting through the lens or optic stimulates production of dopamine within the retina of the wearer's eye.

7 . The system of claim 1 , wherein light transmitting through the lens or optic stimulates production of dopamine and/or serotonin within a brain of the wearer of the lens or optic.

8 . The system of claim 1 , wherein a surface junction between the central optical power zone and the one or more peripheral optical power zones comprises a smooth surface topography.

9 . The system of claim 1 , wherein a surface junction between the central optical power zone and the one or more peripheral optical power zones comprises an uneven surface topography.

10 . The system of claim 1 , wherein an optical power junction between the central optical power zone and the one or more peripheral optical power zones is blended.

11 . The system of claim 1 , wherein an optical power junction between the central optical power zone and the one or more peripheral optical power zones is stepped.

12 . The system of claim 1 , wherein an optical power junction between the central optical power zone and the one or more peripheral optical power zones is of a progressive optical power change.

13 . The system of claim 1 , further comprising a progressive addition zone.

14 . The system of claim 1 , wherein the lens or optic is a single vision lens or optic.

15 . The system of claim 1 , wherein the lens or optic is multifocal.

16 . The system of claim 1 , wherein the lens or optic transmits 40% or more light through the lens or optic as measured within the wavelength range of one or more of: 480 nm+/−30 nm, 450 nm to 520 nm, 650 nm+/−30 nm, or 700 nm+/−30 nm.

17 . The system of claim 1 , wherein the one or more peripheral optical power zones further comprise dispersive electronically switchable liquid crystal.

18 . The system of claim 1 , wherein the one or more peripheral optical power zones provide contrast sensitivity reduction.

19 . The system of claim 1 , wherein the one or more peripheral optical power zones further comprise negative optical power defocus.

20 . The system of claim 1 , wherein the one or more peripheral optical power zones further comprise negative optical power defocus including or incorporating multiple segments.

21 . The system of claim 1 , wherein the one or more peripheral optical power zones further comprise negative optical power highly aspheric lenslets.

22 . The system of claim 1 , wherein the one or more peripheral optical power zones further comprise two outer surface curvatures that are continuous with one another.

23 . The system of claim 1 , further comprising an intermediate optical power zone peripheral to the central optical power zone.

24 . The system of claim 23 , wherein an optical power of the intermediate optical power zone is more minus or less plus optical power compared to the optical power of the central optical power zone, and wherein the optical power of the intermediate optical power zone is less minus or more plus optical power compared to the optical power of the one or more peripheral optical power zones.

25 . The system of claim 1 , wherein the lens or optic is a chromatic aberration focused lens or optic, or wherein the lens or optic is a chromatic aberration refocused lens or optic.

26 . The system of claim 1 , wherein the central optical power zone is rounded, and wherein the rounded central optical power zone is within a range of 6 mm-12 mm in diameter.

27 . The system of claim 1 , wherein one or more optical power junctions located between (1) the central optical power zone, (2) an intermediate optical power zone between the central optical power zone and the one or more peripheral optical power zones, and/or (3) the one more or more peripheral optical power zones, are located on a convex side of the lens or optic.

28 . The system of claim 1 , wherein one or more optical power junctions located between (1) the central optical power zone, (2) an intermediate optical power zone located between the central optical power zone and the one or more peripheral optical power zones, and/or (3) the one or more peripheral optical power zones, are located on a concave side of the lens or optic.

29 . The system of claim 1 , wherein a focus point of the second blue longitudinal chromatic aberration wavelength band is located within a range of 100 microns to 500 microns farther from a back concave side of the lens or optic compared to a focus point of the first blue longitudinal chromatic aberration wavelength band.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2024
From: BLUM, RONALD; BROACH, ANITA; LOEB, JACK
To: NEURORAYS, LLC
Reel/Frame 069042/0982 →
Continuity (29)
Continuation 18914202 · Oct 13, 2024
Continuation 18827786 · Sep 8, 2024
Continuation 18827782 · Sep 8, 2024
Provisional Application 63697560 · Sep 22, 2024
Provisional Application 63684509 · Aug 19, 2024
Provisional Application 63676855 · Jul 29, 2024
Provisional Application 63674219 · Jul 22, 2024
Provisional Application 63673746 · Jul 21, 2024
Provisional Application 63671237 · Jul 14, 2024
Provisional Application 63654566 · May 31, 2024
Provisional Application 63648098 · May 15, 2024
Provisional Application 63639892 · Apr 29, 2024
Provisional Application 63569005 · Mar 22, 2024
Provisional Application 63561266 · Mar 4, 2024
Provisional Application 63553693 · Feb 15, 2024
Provisional Application 63553226 · Feb 14, 2024
Provisional Application 63550852 · Feb 7, 2024
Provisional Application 63627703 · Jan 31, 2024
Provisional Application 63623253 · Jan 20, 2024
Provisional Application 63617363 · Jan 3, 2024
Provisional Application 63609306 · Dec 12, 2023
Provisional Application 63603258 · Nov 28, 2023
Provisional Application 63600139 · Nov 17, 2023
Provisional Application 63548204 · Nov 12, 2023
Provisional Application 63546848 · Nov 1, 2023
Provisional Application 63541243 · Sep 28, 2023
Provisional Application 63540090 · Sep 24, 2023
Provisional Application 63537021 · Sep 7, 2023
Related Publication 20250082960A1 · Mar 13, 2025
References Cited (119)
US 3826751A · Laliberte · 1974 [cited by applicant]
US 5083858A · Girerd · 1992 [cited by applicant]
US 5243460A · Kornberg · 1993 [cited by applicant]
US 5838419A · Holland · 1998 [cited by applicant]
US 5923398A · Goldman · 1999 [cited by applicant]
US 6350275B1 · Vreman et al. · 2002 [cited by applicant]
US 8469512B2 · Croft et al. · 2013 [cited by applicant]
US 8833937B2 · Shehadeh et al. · 2014 [cited by applicant]
US 8911082B2 · Ambler · 2014 [cited by applicant]
US 9028064B2 · Harris · 2015 [cited by applicant]
US 9138595B2 · Savage et al. · 2015 [cited by applicant]
US 9720228B2 · Harrison et al. · 2017 [cited by applicant]
US 9885884B2 · Drobe · 2018 [cited by applicant]
US 10073283B2 · Legerton · 2018 [cited by applicant]
US 10152906B2 · Gutierrez · 2018 [cited by applicant]
US 10219944B2 · Tedford et al. · 2019 [cited by applicant]
US 10386654B2 · Marshall et al. · 2019 [cited by applicant]
US 10444505B2 · Rousseau et al. · 2019 [cited by applicant]
US 10884246B2 · Blum et al. · 2021 [cited by applicant]
US 10884264B2 · Hones et al. · 2021 [cited by applicant]
US 10895735B1 · Feinbloom et al. · 2021 [cited by applicant]
US 10942373B2 · Barrau et al. · 2021 [cited by applicant]
US 11029540B2 · To et al. · 2021 [cited by applicant]
US 11048103B2 · Saylor et al. · 2021 [cited by applicant]
US 11061255B2 · Lau et al. · 2021 [cited by applicant]
US 11065468B2 · Barrau et al. · 2021 [cited by applicant]
US 11086145B2 · Flinders · 2021 [cited by applicant]
US 11099408B2 · McCabe et al. · 2021 [cited by applicant]
US 11131869B2 · Marshall et al. · 2021 [cited by applicant]
US 11420072B2 · He et al. · 2022 [cited by applicant]
US 11446514B2 · Bahmani et al. · 2022 [cited by applicant]
US 11701315B2 · Ishak et al. · 2023 [cited by applicant]
US 11711600B2 · Han et al. · 2023 [cited by applicant]
US 11774784B2 · Barrau et al. · 2023 [cited by applicant]
US 12055797B2 · Newman et al. · 2024 [cited by applicant]
US 12336937B2 · Tedford et al. · 2025 [cited by applicant]
US 20020198577A1 · Jaillet · 2002 [cited by applicant]
US 20100033830A1 · Yung · 2010 [cited by applicant]
US 20100103371A1 · Sarver et al. · 2010 [cited by applicant]
US 20100152849A1 · Degenaar et al. · 2010 [cited by applicant]
US 20120200823A1 · Bandhauer et al. · 2012 [cited by applicant]
US 20130211178A1 · Brigatti et al. · 2013 [cited by applicant]
US 20130222761A1 · Hansen · 2013 [cited by examiner]
US 20140176898A1 · Yi et al. · 2014 [cited by applicant]
US 20140247423A1 · Drobe · 2014 [cited by applicant]
US 20150088231A1 · Rubinfeld et al. · 2015 [cited by applicant]
US 20150142086A1 · Narita · 2015 [cited by applicant]
US 20150234207A1 · Koifman · 2015 [cited by applicant]
US 20160022225A1 · Palmer et al. · 2016 [cited by applicant]
US 20160067086A1 · Tedford et al. · 2016 [cited by applicant]
US 20160216537A1 · Drobe · 2016 [cited by applicant]
US 20160270656A1 · Samec et al. · 2016 [cited by applicant]
US 20160361437A1 · Lucas et al. · 2016 [cited by applicant]
US 20170299898A1 · Gallina et al. · 2017 [cited by applicant]
US 20180017814A1 · Tuan · 2018 [cited by examiner]
US 20180035101A1 · Osterhout · 2018 [cited by examiner]
US 20190204624A1 · Barrau et al. · 2019 [cited by applicant]
US 20190212581A1 · Scherlen et al. · 2019 [cited by applicant]
US 20190258086A1 · Barrau et al. · 2019 [cited by applicant]
US 20200183185A1 · Sankaridurg · 2020 [cited by examiner]
US 20210031051A1 · Kubota · 2021 [cited by examiner]
US 20210157172A1 · Barrau et al. · 2021 [cited by applicant]
US 20210382325A1 · Kubota et al. · 2021 [cited by applicant]
US 20220047887A1 · Honold et al. · 2022 [cited by applicant]
US 20220057651A1 · Segre et al. · 2022 [cited by applicant]
US 20220062634A1 · Masko et al. · 2022 [cited by applicant]
US 20220082860A1 · Guillot et al. · 2022 [cited by applicant]
US 20220111228A1 · Schoutens · 2022 [cited by applicant]
US 20220187628A1 · Valentine et al. · 2022 [cited by applicant]
US 20220233878A1 · Lee et al. · 2022 [cited by applicant]
US 20220252904A1 · Hones, Jr. et al. · 2022 [cited by applicant]
US 20220397774A1 · Barrau et al. · 2022 [cited by applicant]
US 20220413318A1 · Kubota et al. · 2022 [cited by applicant]
US 20230132952A1 · Youngblood et al. · 2023 [cited by applicant]
US 20230204982A1 · Boyles · 2023 [cited by applicant]
US 20230248937A1 · Blair et al. · 2023 [cited by applicant]
US 20230248993A1 · Bahmani et al. · 2023 [cited by applicant]
US 20230389161A1 · Coleman · 2023 [cited by applicant]
US 20240036357A1 · Schianchi et al. · 2024 [cited by applicant]
US 20240272454A1 · Zheleznyak et al. · 2024 [cited by applicant]
US 20240359031A1 · Marshall et al. · 2024 [cited by applicant]
CN 103926710A · 2014 [cited by applicant]
CN 111938911A · 2020 [cited by applicant]
CN 212973238U · 2021 [cited by applicant]
EP 2772794A1 · 2014 [cited by applicant]
EP 3528036A1 · 2019 [cited by applicant]
EP 3528037A1 · 2019 [cited by applicant]
EP 4248925A2 · 2023 [cited by applicant]
EP 4296762A1 · 2023 [cited by applicant]
KR 20130006766U · 2013 [cited by applicant]
KR 102195466B1 · 2020 [cited by applicant]
KR 102436963B1 · 2022 [cited by applicant]
WO 2019109125A1 · 2019 [cited by applicant]
WO 2021105979A1 · 2021 [cited by applicant]
WO 2021116449A1 · 2021 [cited by applicant]
WO 2021252319A1 · 2021 [cited by applicant]
WO 2022094678A1 · 2022 [cited by applicant]
WO 2022187279A1 · 2022 [cited by applicant]
WO 2022219441A1 · 2022 [cited by applicant]
WO 2022258572A1 · 2022 [cited by applicant]
WO 2023186146A1 · 2023 [cited by applicant]
WO 2024094884A1 · 2024 [cited by applicant]
Cardinal Intellectual Property Patent Search Report dated Nov. 4, 2024. [cited by applicant]
Chakraborty, R., et al.; Axial length reduction and choroidal thickening with short-term exposure to cyan light in human subjects; Ophthalmic Physiol Opt. 2024;00:1-19. https://doi.org/10.1111/opo.13390. [cited by applicant]
National Academies of Sciences, Engineering, and Medicine. 2024. Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease. Washington, DC: The National Academies Press. https://doi.org/10.17226/27734. [cited by applicant]
Visible Bandpass Filters; Optical Filter Shop; retrieved at https://opticalfiltershop.com/product-category/bandpass-filter/visible-bandpass-filters-390nm-to-750nm/?srsltid=AfmBOoq17fx_K3qa6-4IEMggf0z4wh0-EXqLU41U1dkCunE… [cited by applicant]
Application No. PCT/US2024/051175, International Search Report and Written Opinion dated Nov. 25, 2024. [cited by applicant]
Application No. PCT/US2024/053151, International Search Report and Written Opinion dated Jan. 2, 2025. [cited by applicant]
Application No. PCT/US2024/056407, International Search Report and Written Opinion dated Jan. 17, 2025. [cited by applicant]
Application No. PCT/US2024/045750, International Search Report and Written Opinion dated Dec. 16, 2024. [cited by applicant]
Application No. PCT/US2024/045751, International Search Report and Written Opinion dated Dec. 16, 2024. [cited by applicant]
Application No. PCT/US2024/057354, International Search Report and Written Opinion dated Feb. 3, 2025. [cited by applicant]
Application No. PCT/US2025/012142, International Search Report and Written Opinion dated Mar. 5, 2025. [cited by applicant]
Capovilla, G.; Effectiveness of a particular blue lens on photoparoxysmal response in photosensitive epileptic patients; Ital J. Neurol Sci (1999) 20:161-166. [cited by applicant]
www.dopavision.com/product/, visited Sep. 11, 2024. [cited by applicant]
Akerman, D., Predicting the Onset of Myopia in Children, Review of Myopia Management, Jul. 15, 2024, https://reviewofmm.com/predicting-the-onset-of-myopia-in-children/, downloaded May 30, 2025. [cited by applicant]
Liu, Z., et al., The Effects of Repeated Low-Level Red-Light Therapy on the Structure and Vasculature of the Choroid and Retina in Children with Premyopia, Ophthalmol Ther 13:739-759 (2024), https://doi.org/10.1007/s401… [cited by applicant]
Lumivision & Wellbeing: Myproclear webpage; https://lumi-visionandwellbeing.co.uk/red-light-therapy-for-myopical-control/; downloaded May 19, 2025. [cited by applicant]
Mutti, D., et al., Predicting the onset of myopia in children by age, sex, ethnicity: Results from the CLEERE Study, Optom Vis Sci. Apr. 1, 2024;101(4):179-186, https://pmc.ncbi.nlm.nih.gov/articles/PMC11060695/, downlo… [cited by applicant]